78 results on '"Pedrosa, Marcos"'
Search Results
2. Current state-of-the-art and gaps in platform trials: 10 things you should know, insights from EU-PEARL
3. Identification of Fast Progressors Among Patients With Nonalcoholic Steatohepatitis Using Machine Learning
4. Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study
5. NASHmap: clinical utility of a machine learning model to identify patients at risk of NASH in real-world settings
6. The Cost of Diagnosing and Managing Non-alcoholic Steatohepatitis in Europe and the United States
7. Magnetic resonance elastography (MRE) demonstrate the strongest correlation with digital pathology and NASH CRN fibrosis assessments, compared to transient elastography and other assessed non-invasive tests (NITs)
8. Longitudinal ALT trajectories are generally stable among patients with non-alcoholic fatty liver disease (NAFLD): an investigation using artificial recurrent neural networks
9. Second harmonic generation microscopy can quantify and subclassify early stages of NASH fibrosis progression: data from a screen-failure cohort of a NASH phase 2 study
10. A adoção do Programa Mais Médicos em Pernambuco: Uma análise sobre a decisão local por implementar uma política federal
11. 1055-P: The Machine Learning Prediction Model NASHmap Identifies Higher Insulin Resistance in Type 2 Diabetes Mellitus (T2DM) Patients at Risk for Nonalcoholic Steatohepatitis (NASH)
12. The global epidemiology of nonalcoholic steatohepatitis (NASH) and associated risk factors–A targeted literature review
13. Development of a novel machine learning model to predict presence of nonalcoholic steatohepatitis
14. Lead Authors and Contributors
15. Predictive modelling to identify and characterize fast progressors among patients with non-alcoholic steatohepatitis (NASH)
16. 1487-P: Increased Identification of NASH among Diabetic and Nondiabetic Patients through Machine Learning in Real-World Settings
17. A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial
18. Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosis
19. Implementation of the ECHO® telementoring model for the treatment of patients with hepatitis C
20. Corrigendum: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents
21. Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents
22. Improved Survival Among all Interferon-α-Treated Patients in HCV-002, a Veterans Affairs Hepatitis C Cohort of 2211 Patients, Despite Increased Cirrhosis Among Nonresponders
23. Development and Performance of an Algorithm to Estimate the Child-Turcotte-Pugh Score From a National Electronic Healthcare Database
24. Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV)
25. High SVR Rates Among US Patients Regardless of Race or Ethnicity in HCV GT1 Patients Receiving the Label-Recommended Regimen of Ombitasvir/Paritaprevir/r+Dasabuvir±Ribavirin: Integrated Safety and Efficacy Analysis
26. Efficacy of Ombitasvir/Paritaprevir/ and Dasabuvir +/-Ribavirin in Patients Receiving Concomitant Acid-Reducing Agents in Phase 3 Trials
27. Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia
28. 1014 Improvement in Liver Function and Non-Invasive Estimates of Liver Fibrosis 48 Weeks After Treatment With Ombitasvir/Paritaprevir/R, Dasabuvir and Ribavirin in HCV Genotype 1 Patients With Cirrhosis
29. Management of Hemoglobin Decrease in Patients Treated With ABT-450/Ritonavir/Ombitasvir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Patients
30. Safety Comparison of 12- And 24-Week Treatments in HCV Genotype 1-Infected Patients With Cirrhosis: Results From Turquoise-II
31. Low Incidence of Hyperbilirubinemia Events With ABT-450/r-Ombitasvir and Dasabuvir With or Without Ribavirin in HCV Genotype-1 Infected Patients
32. Normalization of Liver-Related Laboratory Parameters in HCV Genotype 1-Infected Patients With Cirrhosis After Treatment With ABT-450/R/Ombitasvir, Dasabuvir and Ribavirin
33. Evidence-based Review of Gastrointestinal Bleeding in the Chronic Kidney Disease Patient
34. Mo1059 Interim Analysis of HCC Screening and Survival in 1131 Veterans Diagnosed With HCC From 2008-2010
35. Mo1036 Development and Validation of a Virtual Child-Turcotte-Pugh Score to Assess Liver Disease Severity in an Administrative Healthcare Database
36. Endoluminal bariatric techniques
37. Sa1840 Assessment of Portal Hypertensive Enteropathy (PHE) Using Probe-Based Confocal Laser Endomicroscopy (pCLE)
38. Sphincter of Oddi manometry
39. Frequency of species of Eimeria in females of the holstein-friesian breed at the post-weaning stage during autumn and winter
40. Drug-eluting/biodegradable stents
41. Enteral stents
42. GI endoscopes
43. Devices to improve colon polyp detection
44. Enhanced ultrasound imaging
45. Endoscopic simulators
46. Autofluorescence imaging
47. Computer-assisted personalized sedation
48. U.S. Multicenter Pilot Study of Daily Consensus Interferon (CIFN) Plus Ribavirin for “Difficult-to-Treat” HCV Genotype 1 Patients
49. Automated endoscope reprocessors
50. Endoscopic tattooing
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.